TY - JOUR
T1 - Treatment of Geographic Atrophy
T2 - What’s on the Horizon?
AU - Thorell, Mariana R.
AU - Rosenfeld, Philip J.
N1 - Funding Information:
This study was supported in part by grants from Alexion Pharmaceuticals, GlaxoSmithKline, Acucela, Advanced Cell Technology, and Carl Zeiss Meditec, and consulting fees from Acucela to Philip Rosenfeld.
Publisher Copyright:
© 2014, Springer Science + Business Media New York.
PY - 2014/3/1
Y1 - 2014/3/1
N2 - Currently, there is no treatment to stop the progression of geographic atrophy, the advanced form of non-exudative (dry) age-related macular degeneration. Several promising therapies are being investigated in clinical trials such as antioxidants, neuroprotection agents, complement inhibitors, vascular enhancers, visual cycle modulators, and stem cell therapies. This review discusses the possible treatments that may potentially be available in the future to prevent disease progression.
AB - Currently, there is no treatment to stop the progression of geographic atrophy, the advanced form of non-exudative (dry) age-related macular degeneration. Several promising therapies are being investigated in clinical trials such as antioxidants, neuroprotection agents, complement inhibitors, vascular enhancers, visual cycle modulators, and stem cell therapies. This review discusses the possible treatments that may potentially be available in the future to prevent disease progression.
KW - Age-related macular degeneration (AMD)
KW - Cell therapies
KW - Dry AMD
KW - Ophthalmology
KW - Treatment of geographic atrophy
UR - http://www.scopus.com/inward/record.url?scp=85081081561&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081081561&partnerID=8YFLogxK
U2 - 10.1007/s40135-013-0036-y
DO - 10.1007/s40135-013-0036-y
M3 - Article
AN - SCOPUS:85081081561
VL - 2
SP - 20
EP - 25
JO - Current Ophthalmology Reports
JF - Current Ophthalmology Reports
SN - 2167-4868
IS - 1
ER -